Tag: US14070B3096

Capricor Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that senior management will participate in the following upcoming investor conferences.

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET –

– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET –

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsUS14070B3096

Bandwidth Announces Kimberly McLachlan as Chief Revenue Officer

10th Huawei ICT Competition Concludes with Student Winners from 49 Countries and Regions and a Record 220,000 Participants

Selagine Plasma to Advance Pooled Plasma Eye Drops for Moderate-to-Severe Dry Eye

Tag: US14070B3096

Capricor Therapeutics to Present at Upcoming Investor Conferences

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us